{"schema_version":"1.0","type":"article","title":"瘦瘦針翻車？導致胰臟炎？","url":"https://drugnews.com.tw/articles/2026-04-04-dcard-261232633.html","markdown_url":"https://drugnews.com.tw/articles/2026-04-04-dcard-261232633.md","lang":"zh-Hant","date":"2026-04-04","publish_at":"2026-04-04T10:30:00+08:00","updated_at":"2026-04-04","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","GLP-1","臨床數據","生技投資"],"summary":"GLP-1 類藥物近兩年幾乎成了全球醫療市場最耀眼的明星。從 liraglutide（利拉魯肽）、semaglutide（司美格魯肽），到雙重受體機制的 tirzepatide（替爾泊肽），這一波藥物不只改變了第二型糖尿病治療，也快速跨入體重管理、心血管風險降低等更大的市場。","key_points":[],"facts":[],"sections":["當減重神藥撞上監管逆風：英國強化致命胰臟炎警示，FDA 點名 Novo Nordisk（諾和諾德）藥物警戒失靈","英國先出手：不只是提醒，而是把警示門檻整體往前拉","真正棘手的地方：胰臟炎早期症狀，和常見腸胃副作用太像","美國 FDA 的重點更狠：不是只看藥，而是直接質疑藥物警戒系統","更嚴重的是：連自殺意念與死亡個案，都曾被延遲或錯誤處理","這裡最容易被誤讀：通報違規，不等於 FDA 已認定 GLP-1 會增加自殺風險","真正值得警惕的，不只是某個分子，而是整套藥物警戒能不能承受爆量","把英國與美國放在一起看，監管核心其實很一致","下一輪競爭，不只比減重幅度，還要比風險治理能力","寫在最後：GLP-1 不會退場，但監管已經進入更成熟、更殘酷的下一階段"],"references":[{"title":"各公司官網＆公開資料","source":"","date":"","url":""},{"title":"Novo Nordisk Inc. - 717576 - 03/05/2026","source":"FDA","date":"","url":""},{"title":"Postmarketing Adverse Drug Experience Reporting Requirements","source":"","date":"","url":""},{"title":"www.fda.gov","source":"","date":"","url":""},{"title":"GOV.UK","source":"","date":"","url":""},{"title":"Updated product information for healthcare professionals and patients regarding the small risk of severe acute pancreatitis in patients taking GLP-1s.","source":"","date":"","url":""},{"title":"www.gov.uk","source":"","date":"","url":""},{"title":"GOV.UK","source":"","date":"","url":""},{"title":"The product information for all Glucagon-Like Peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists has been further updated to highlight the potential risk of severe acute pancreatitis wit","source":"","date":"","url":""},{"title":"www.gov.uk","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：瘦瘦針翻車？導致胰臟炎？（圖 1）","url":"https://drugnews.com.tw/assets/articles/dcard-261232633/dcard-01.webp"},{"alt":"Dcard 原圖：瘦瘦針翻車？導致胰臟炎？（圖 2）","url":"https://drugnews.com.tw/assets/articles/dcard-261232633/dcard-02.webp"},{"alt":"Dcard 原圖：瘦瘦針翻車？導致胰臟炎？（圖 3）","url":"https://drugnews.com.tw/assets/articles/dcard-261232633/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/dcard-261232633/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-04-04）。瘦瘦針翻車？導致胰臟炎？。https://drugnews.com.tw/articles/2026-04-04-dcard-261232633.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-04-04-dcard-261232633-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}